OPTR Financial Facts
Consolidated net income (loss): -26.87MNet loss attributable to noncontrolling interest: 0
See Full Income Statement
Accrued expenses: 27.25M
Total Optimer Pharmaceuticals, Inc. stockholders' equity: 89.08M
See Full Balance Sheet
Optimer Pharmaceuticals, Inc. (OPTR) Earnings
|
Expand Research on OPTR
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +18.6% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +0.1% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/1/13  |
 |
Q213 | -$0.55 | -$0.62 | +$0.07 | $20.1M | $21.31M | N/A |  | | Details |
| 5/9/13 |
|
Q113 | -$0.65 | -$0.42 | -$0.23 | $19.4M | $21.09M | N/A | | | Details |
| 2/28/13 |
|
Q412 | $0.02 | -$0.38 | +$0.40 | $19.5M | $18.05M | N/A | | | Details |
| 11/1/12 |
Q312 | -$0.56 | -$0.64 | +$0.08 | $17.89M | $16.03M | N/A | | | Details | |
| 7/31/12 |
|
Q212 | -$0.01 | $0.05 | -$0.06 | $49.8M | $49.47M | N/A | | | Details |
| 5/10/12 |
Q112 | -$0.23 | -$0.38 | +$0.15 | $14.4M | $28.77M | N/A | | | Details | |
| 3/7/12 |
|
Q411 | $0.28 | $0.11 | +$0.17 | $64.6M | $43.19M | N/A | | | Details |
| 11/3/11 |
|
Q311 | -$0.57 | -$0.52 | -$0.05 | $11.1M | $5.44M | N/A | | | Details |
